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The presence of virulence factors (VFs) and mechanisms of quinolones and macrolide resistance was analyzed in Campylobacter
spp. from a pediatric cohort study in Lima. In 149 isolates (39 Campylobacter jejuni and 24 Campylobacter coli from diarrheic cases;
57C. jejuni and 29C. coli from controls), the presence of the cdtABC and cadF genes and iammarker was established. Nalidixic acid,
ciprofloxacin, erythromycin, and azithromycin susceptibilities were established in 115 isolates and tetracycline-susceptibility was
established in 100 isolates.The presence of mutations in the gyrA, parC, and 23S rRNA genes was determined.The cadF gene and all
genes from the cdtABC operonwere significantlymore frequent amongC. jejuni (𝑃 < 0.0001); the iammarker wasmore frequent in
C. coli (𝑃 < 0.0001). No differences were observed in VFs between cases and controls. Almost all isolates were tetracycline-resistant;
nalidixic acid and ciprofloxacin resistance reached levels of 90.4% and 88.7%, respectively. Resistance to macrolides was 13% (C.
jejuni 4.3%; C. coli 26.1%). Resistance to ciprofloxacin was related to GyrA Thr86 substitutions, while 13 of 15 macrolide-resistant
isolates possessed a 23S rRNA mutation (A2075G). Differences in the presence of VFs and alarming levels of resistance to tested
antimicrobial agents were observed among C. jejuni and C. coli.
1. Introduction
Campylobacter spp. ranks among the most relevant causes
of diarrheal illness worldwide, with recent estimations of
around 166,000 cases/year, including 31,700 Guillain-Barre´
Syndromes, which lead to 37,604 deaths and 3,733,822
Disability Adjusted Life Years (DALYs) [1]. In addition,
other severe sequelae, such as Miller-Fisher syndrome (a
subtype of Guillain-Barre´ Syndrome), have been described
[2, 3]. Although other Campylobacter species have clini-
cal relevance, Campylobacter jejuni and Campylobacter coli
have classically been considered the most relevant human
pathogens belonging to this genus [2].
Although relatively little is known about the virulence of
Campylobacter spp., these microorganisms possess different
virulence factors (VFs) related tomotility, adhesion, invasion,
toxin-activity, immune evasion, and iron-uptake, among
others [2]. Thus, while factors, like the cadF gene or the iam
locus, are involved in different invasion steps [4, 5] others
such as the cytolethal distending toxin, a tripartite toxin
encoded in the cdtA, cdtB, and cdtC genes which is also
present in other microorganisms [6], block the CDC2 kinase,
leading to progressive cellular distension which results in cell
death [2].
Diarrhea by Campylobacter spp. is usually a self-limited
disease which only requires oral rehydration. However, in
some cases (immunocompromised patients, long duration
of symptoms, and patients with severe complications) the
use of antimicrobial agents may be required [7]. Currently,
macrolides are the drugs of choice, with fluoroquinolones as
second-line drugs quinolones [7]. However, the presence of
quinolone-resistantCampylobacter spp. isolates is not a novel
event [8–10]. Moreover, the development of quinolone resis-
tance during antibiotic treatment has also been reported [7,
11]. In general, the amino acid substitutions in the A subunits
(GyrA and ParC) of the DNA-Gyrase and Topoisomerase
IV are the most relevant mechanisms of quinolone resis-
tance [12]. In addition, alterations in cytoplasmic quinolone
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uptake and a series of transferable mechanisms of quinolone
resistance (TMQR) also play a role in the increasing levels
of quinolone resistance [12, 13]. Interestingly, Campylobacter
spp. does not possess a Topoisomerase IV, and thus a single
amino acid substitution at GyrA may result in high levels
of quinolone resistance [12]. The most frequently described
amino acid substitution in Campylobacter spp. affects posi-
tions 86 and 90 of GyrA, with the amino acid change Thr86-
Ile being the most widely described [8, 14]. In addition,
the relevant role of CmeABC, a resistance-nodulation-cell
division (RND) efflux pump, has also been described [15].
Finally, to the best of our knowledge, up to now TMQR has
not been described in Campylobacter spp.
Regarding macrolides, the isolation of resistant Campy-
lobacter spp. is increasingly reported [16, 17], being especially
of note in isolates of an animal origin [10, 18]. In both animal
and human isolates, macrolide resistance is more frequent in
C. coli [9, 10, 16, 18]. Macrolides interact with the 50S subunit
of the ribosome, inhibiting protein elongation and thus
protein synthesis [19]. Alterations at the interaction points of
the 23S rRNA, L4, or L22 proteins result in the development of
macrolide resistance in a wide range of microorganisms [19].
However, the clinical relevance of mutations in the 23S rRNA
gene is closely related to the copy number of the gene that
each microorganism possesses [19]. Thus, in Campylobacter
spp., which has 3 copies of the 23S rRNA gene, mutations
in more than one gene copy results in the development
of macrolide resistance [20]. Mutations such as A2074G/T,
A2075G, andA2076G (equivalent toA2057G/T,A2058G, and
A2059G following E. coli numeration) have been described
in Campylobacter spp., with those affecting A2075 being the
most frequently detected [14, 16, 20]. Although L4 and L22
amino acid substitutions, such as the amino acid changes
Gly74-Asp in L4 or Ala86-Glu in L22 or the insertions
86::Ala-Arg-Ala-Arg::87 or 98::Thr-Ser-His::99 in L22, have
been related to the acquisition of macrolide resistance in
Campylobacter spp. [14, 21], the role of alterations at L4
and L22 seems to be of less relevance in Campylobacter
clinical isolates [16, 20]. In fact, it has been described that
these alterations may lead to a negative effect on bacterial
fitness levels [19]. Additionally, extrusion of macrolides from
the bacterial cytoplasm by CmeABC has also been reported
[21]. To the best of our knowledge, the erm(B) gene, which
may be encoded within a transferable multidrug-resistant
genomic island, is currently the only transferable mechanism
ofmacrolide resistance (TMMR) described inCampylobacter
spp. [22].
The aim of this study was to determine the presence
of several VFs and the levels and molecular mechanisms
of resistance to quinolones and macrolides in a series of
Campylobacter spp. isolates recovered from children less than
18 months of age, in a periurban area of Lima, Peru.
2. Material and Methods
2.1.Microorganisms. One hundred forty-nineCampylobacter
spp. (Supplemental material, available online at https://doi
.org/10.1155/2017/7848926) recovered from feces of children
less than 18 months old with (63 isolates) and without (86
isolates) diarrhea, during a double-blind controlled trial of
bovine lactoferrin for the prevention of diarrhea in children
in Lima between January 2008 andMay 2011, were included in
the study [25]. After initial culture at 42∘C in chocolate agar
and microaerophilic conditions, followed by Campylobacter
phenotypic identification (evaluation of colony morphology,
Gram staining, and oxidase and catalase determinations),
DNA was extracted by direct boiling of 1 colony of each
isolate and both DNA and microorganisms were frozen
until analysis. A C. coli clinical isolate kindly provided
by the Instituto Nacional de Salud from Lima (Peru) and
C. jejuni ATCC 33560, Escherichia coli ATCC 25922, and
Staphylococcus aureus ATCC 25923 were used as control.
2.2. Species Determination. C. coli and C. jejuni were iden-
tified by PCR using the primers and conditions previously
described (Table 1). The amplified products were analyzed
in a 1.5% electrophoresis gel and stained with SYBR Safe
(Invitrogen, Eugene, USA). Amplified products were selected
at random and sequenced (Macrogen, Seoul, Korea) as
quality control.
2.3. Virulence Factors. The presence of the cadF, cdtA, cdtB,
and cdtC genes plus that of the full cdt cluster and the iam
marker was determined by PCR [23] (Table 1).
2.4. Antimicrobial Susceptibility. The antimicrobial suscep-
tibility to azithromycin (Azm, 15𝜇g), erythromycin (Ery,
15 𝜇g), nalidixic acid (Nal, 30 𝜇g), ciprofloxacin (Cip,
5 𝜇g), and tetracycline (Tc, 30 𝜇g) was established by disk
diffusion following the EUCAST guidelines in the micro-
organisms recovered from frozen stock. The EUCAST (Ery,
Cip, and Tc) (http://www.eucast.org/fileadmin/src/media/
PDFs/EUCAST files/Breakpoint tables/v 6.0 Breakpoint
table.pdf) and BSAC (Nal) ( http://bsac.org.uk/wp-content/
uploads/2012/02/Table-20.pdf) guidelines were used to
interpret the obtained diameter. In the absence of established
breakpoints, Azm was interpreted according to the following
scheme: susceptible ≥ 18mm and resistant ≤ 17mm.
2.5. Analysis ofMutations in the gyrA and 23S rRNAGenes. In
strains with susceptibility data, the presence of mutations in
the gyrA and 23S rRNA genes was determined by PCR using
the primers and conditions previously described (Table 1). In
the case of the gyrA gene, the DNAs initially obtained for
the nongrowing isolates were also included in the study. The
amplified products were recovered and purified (PCR Clean-
Up System (Promega, Madison,WI)) following themanufac-
turer’s instructions. Both strands of purified products were
sequenced (Macrogen, Seoul, Korea).
2.6. Statistical Analysis. Fisher’s exact test was used to analyze
the data.
3. Results
3.1. Identification. Of the total strains analyzed, 96 (64.4%)
were C. jejuni and 53 (35.6%) C. coli; of these, 39 C. jejuni and
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Table 1: Primers and PCR conditions used in the present study.
Target Description Primer (5耠-3耠) Size (bp) Ann Cycles Ref
Identification
C. coli∗ AGGCAAGGGAGCCTTTAATC 364 61 30 [23]TATCCCTAT CTACAAATTCGC
C. jejuni∗ CATCTTCCCTAGTCAAGCCT 773 61 30 [23]AAG ATATGGCACTAGCAAGAC
Resistance
gyrA DNA-Gyrase subunit A ATGATGAGGCAAAAAGAGA 410 55 30 [8]TAAACTATGAGGTGGGATGT
23S rRNA GTAAACGGCGGCCGTAACTA 699 52 35 [24]GACCGAACTGTCTCACGACG
Virulence
cadF Campylobacter adhesin to fibronectin TTGAAGGTAATTTAGATATG 400 45 30 [23]CTAATACCTAAAGTTGAAAC
cdtABC Cytolethal distending Toxin subunits ABC GGAAATTGGATTTGGGGCTATACT 1215 55 30 [23]TTGCACATAACCAAAAGGAAG
cdtA Cytolethal distending Toxin subunit A CCTTGTGATGCAAGCAATC 370 42 30 [23]ACACTCCATTTGCTTTCTG
cdtB Cytolethal distending Toxin subunit B GTTAAAATCCCCTGCTATCAACCA 495 42 30 [23]GTTGGCACTTGGAATTTGCAAGGC
cdtC Cytolethal distending Toxin subunit C CGATGAGTTAAAACAAAAAGATA 182 42 30 [23]TTGGCATTATAGAAAATACAGTT
iam1 Invasio´n-associated marker 1 GCGCAAAATATTATCACCC 518 52 30 [23]TTCACGACTACTATGCGG
iam2 Invasion-associated marker 2 GGCGCTTTAGGGAAGCTG 1360 52 30 [23]CTTTAAATTGAATCACGGG
iam3 Invasion-associated marker 3 TGAGGAGCTAAGGGTGCAAA 270 52 30 [23]AATACTGATATTTTCCACAT
bp: base pair; Ann: annealing; Ref: reference. ∗Primers used in a Multiplex PCR.
Table 2: Samples type.
𝑛 (%)
Diarrhea
(𝑛 = 63)
Asymptomatic control
(𝑛 = 86)
Total
(𝑛 = 149)
C. jejuni 39 (61.9) 57 (66.3) 96 (64.4)
C. coli 24 (38.1) 29 (33.7) 53 (35.6)
Total 63 (100) 76 (100) 149 (100)
24 C. coli were from diarrheic cases, while 57 C. jejuni and 29
C. coli were from healthy controls (Table 2). No differences
were found in relation to sex in the prevalence of C. jejuni
and C. coli.
3.2. Virulence Factor Analysis. The cadF gene was present in
all the isolates except 2 C. jejuni isolates from the control
group. The complete cdtABC operon was amplified in 87
(58.4%) isolates (85 C. jejuni and 2 C. coli) being significantly
more frequent among C. jejuni (88.7% versus 3.7%) (𝑃 <
0.001). Regarding the cdt genes, cdtB was present in 121
isolates (81.2%), while cdtA and cdtC were present in 102
(67.1%) and 103 (68.7%) isolates, respectively. Independently,
all 3 genes were significantly more present in C. jejuni than
in C. coli (𝑃 < 0.0001) (Table 3). In 1 C. jejuni full cdtABC
amplification was achieved; however cdtA, cdtB, or cdtC
genes could not be amplified. Similarly 11 C. jejuni and 4 C.
coli amplify all genes in independent manner, but no PCR
product was obtained when the primers for cdtABC were
used. Regarding the iammarker the 3 sequences sought were
more frequently detected in C. coli than in C. jejuni (93.1%,
89.7%, and 96.6% versus 4.0%, 4.0%, and 5.1% for iam1, iam2,
and iam3, resp.) (𝑃 < 0.0001). All 3 sequences were detected
concomitantly in the 89.7% of C. coli and 4.0% of C. jejuni
(𝑃 = 0.0001) (Table 3). No differences in the prevalence of
soughtVFswere found among isolates from cases and control
or sex groups.
3.3. Antimicrobial Resistance Levels. The resistance levels to
quinolones and macrolides were determined in 115 isolates
(69 C. jejuni, 46 C. coli) able to grow from frozen stock, while
the resistance levels to Tc were also established in 100 out of
these isolates.
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Regarding quinolones, the results showed almost full
concordance (only 2 NalR C. jejuni isolates from the diarrhea
group were not resistant to Cip) and also extremely high
levels of resistance (104 isolates, 90.4% to Nal; 102 isolates,
88.7% to Cip). Likewise, extremely high levels of resistance
to Tc were observed (96 isolates, 96.0%). Meanwhile, only 15
(13.0%) isolates showed resistance to both Ery and Azm. All
macrolide-resistant microorganisms also showed resistance
to the quinolones tested (Table 4).
Analysis by species only showed statistically significant
differences in those regarding macrolide resistance. Thus
C. coli showed higher levels of resistance than C. jejuni
(12 isolates, 26.1% versus 3 isolates, 4.3%; P: 0.0012). The
significance was alsomaintained betweenC. coli andC. jejuni
from the control group (6 isolates, 24% versus 1 isolate, 2.6%;
𝑃 = 0.0119), with borderline significance between C. jejuni
and C. coli from the diarrhea group (𝑃 = 0.0521) (Table 4).
No association was observed between sex and macrolide
or quinolone resistance. No association was found between
susceptibility/resistance and a higher or lower presence of the
VFs sought.
3.4. Analysis of the Mechanisms of Resistance. The analysis
of the gyrA gene showed the presence of Thr86-Ile amino
acid substitutions in the 102 NalRCipR and in 1 NalRCipS
isolates, while in another C. jejuni, NalRCipS, the Thr86-Ala
substitution was observed. Additionally, 3 C. jejuni isolates
exhibiting susceptibility to both quinolones also possessed
theThr86-Ile substitution.Meanwhile, for the 34 nongrowing
isolates the presence of Thr86-Ile was observed in 28 cases.
Resistance to macrolides was related to the presence of
the base change A2075G in 13 out of 15 (86.7%) macrolide-
resistant isolates. Interestingly in 2 out of these 13 isolates
(both C. coli) double peaks were observed, highlighting the
presence of mutations in only 1 or 2 of the 3 Campylobacter
spp. 23S rRNA gene copies. Finally, 1 of the 2 macrolide-
resistant isolates without a mutation in the 23S rRNA gene
had an Ery halo of 19mm and an azithromycin halo of
16mm, while the remaining isolate had no halo to both of the
macrolides tested.
4. Discussion
4.1. Microorganisms. Although a reduction in the burden of
diarrhea has been observed in Peru, it has been estimated
that in 2015 diarrhea led to 514 deaths in children less
than 5 years of age (0.8 deaths/1,000 live births), account-
ing for 4.9% of deaths in this population (http://apps.who
.int/gho/data/node.main.COCD?lang=en). In Peruvian rural
zones and in periurban areas of Lima and other cities the lack
of adequate sanitation conditions supports the high preva-
lence of diarrheic diseases. In these areas,Campylobacter spp.
ranks after enteric viruses and enteropathogenic E. coli as
etiologic cause of diarrhea [25].
The proportions of C. jejuni and C. coli in our study are
quite different from previous studies performed in this area.
Thus, analyzing 4652 Campylobacter spp. collected between
January 2001 and December 2010 the presence of 3856 C.
jejuni (82.9%) and 554 C. coli (11.9%) was detected together
with other Campylobacter spp. [17]. Although the spread of
a C. coli clone in the area may be suggested, there is no clear
reason for these differences.
4.2. Virulence Factors. Previous studies have shown that
almost all C. jejuni and C. coli possess the cadF gene [26,
27]. In this line, our results are as expected. Regarding
the presence of 2 cadF negative C. jejuni isolates, although
possible insertion inactivation or deletion can not be ruled
out, the presence of a polymorphismwhichmight affect PCR-
positivity has been previously described [27]. Meanwhile,
both in the case of cdt and iam, the use of different primer
sets increased the reliability of PCR results, confirming the
presence of significant differences in the carriage of these VFs
among C. coli and C. jejuni.
Although presence of polymorphisms in the primers
annealing regions may not be ruled out, while all C. jejuni
presenting the cdt operon possessed the 3 components, a
series ofC. coliwere positives for cdtB but not for cdtA and/or
cdtC.This is a relevant finding because the lack of either cdtA
or cdtC leads to an impaired production of CDT [28].
Some studies have shown that the IAM region was more
frequent in C. coli independently of whether it was from
children (83.3%) or chicken (100%), being also frequent
(54.7%) in C. jejuni from chicken but almost absent (1.3%)
in those isolated from children [23]. In accordance with
this, our results showed that C. coli carried the IAM region
significantly more frequently than C. jejuni.
4.3. Antimicrobial Resistance. Symptomatic and asympto-
matic Campylobacter spp. infections have been involved in
reduced weight gain over three-month periods in children
[29]. Although symptomatic infections weremarginally asso-
ciated with reduced linear growth over nine-month periods,
the severity of the episodeswas correlatedwith greater deficits
in both weight gain and linear growth, demonstrating the
need for early control of Campylobacter infections [29].
A survey performed in Peru between 2001 and 2010
showed an increase in Cip resistance levels of both C. jejuni
and C. coli. In Lima, the levels of Cip resistance were 73.1%
and 48.1% for C. jejuni and C. coli, respectively, in the period
2001–2005, with those values rising to 91.1% and 87.4% in the
period 2006–2010, respectively [17]. The most recent values
are in accordance with the levels of Cip resistance detected in
our isolates.
Similar to that described in other geographical areas [30],
our results showed extremely high resistance levels to Tc of
100% among C. coli and 90% among C. jejuni. Though not
used in the treatment of Campylobacter infections in young
children, this scenario shows that Tc has lost all its utility in
the treatment of Campylobacter spp. in Peru.
The macrolide resistance was higher in C. coli than in
C. jejuni, similar to what has been observed in other studies
[16, 17]. Overall, our macrolide resistance levels were higher
than those previously reported in the area of Lima (C. jejuni
4.3% versus 1.9%; C. coli 26.1% versus 5.3% and 5.8%, Ery and
Azm, resp.) [17]. In a previous study a significant increase
in the C. coli Azm resistance over time in Lima was of
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note [17]. Our data confirm this trend and also show an
increase in macrolide resistance among C. jejuni. All the
macrolide-resistant isolates detected also showed resistance
to quinolones, highlighting the need of new antimicrobial
agents to treat Campylobacter infections.
4.4. Mechanisms of Quinolone and Macrolide Resistance.
While most microorganisms possess 2 quinolone-targets
(DNA-Gyrase and Topoisomerase IV), Campylobacter spp.
only possess one of the DNA-Gyrases; thus a single target-
mutation may lead to both high Nal and Cip resistance
levels [8, 12, 31]. The GyrA amino acid change Thr86-Ile
has been extensively described in Campylobacter spp. [8, 31].
The phenotype NalRCipS was observed in two C. jejuni, in
one case related to the Thr86-Ala substitution. It has been
observed that theThr86-Ala substitution leads to increases in
the Nal MIC, in some cases just low-bordering the resistance
breakpoint, with a lesser effect on the Cip resistance levels
[31]. In addition, microorganisms either having the wild
type presence of Ala [32] or presenting a mutation leading
to the presence of Ala in the equivalent position of GyrA
[33] present Nal resistance patterns, albeit usually lower
than those produced by other amino acid substitutions, and
decreased susceptibility to fluoroquinolones. This may be
related to lower alterations in the hydrophobic patterns of
the DNA-Gyrase interaction point [12, 32]. The remaining
NalRCipS as well as the 3 NalSCipS isolates carrying the
Thr86-Ile substitution might be explained by an enhanced
quinolone uptake that may be due to a malfunction of
efflux pumps or to enhanced outer membrane permeabil-
ity.
The presence of mutations at position A2075 was found
in all but 2 macrolide-resistant isolates. In two cases the data
suggested the presence of heterozygote isolates, with only one
or two mutated 23S rRNA. In these cases, as 33–66% of the
ribosomes were resistant to the action of the macrolides, the
isolates remained resistant to bothAzmandEry.Thepresence
of 2macrolide-resistant isolates without alterations in the 23S
rRNA gene may be due to an overexpression of the CmeABC
[21, 34]. This option is highly probable in the isolate having
a borderline macrolide halo [34], while another explanation,
such as the presence of amino acid substitutions in L4 or L22,
might be considered in the other case [19]. In addition, the
presence of TMMR, such as Erm(B) recently described in
Campylobacter genus [22] cannot be ruled out.
In summary, the present data demonstrates high levels
of Tc and quinolone resistance in both C. jejuni and C. coli
and increasingmacrolide resistance amongC. coli. Moreover,
the concomitant resistance to quinolones and macrolides is
serious and may lead to the expansion of difficult-to-treat
Campylobacter spp. isolates. The implementation of control
measures which result in a more rational antimicrobial use
in human infections, but especially in veterinary settings, is a
priority.
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